<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568944</url>
  </required_header>
  <id_info>
    <org_study_id>R21DE020916</org_study_id>
    <secondary_id>Pro00000394</secondary_id>
    <secondary_id>R21DE020916</secondary_id>
    <nct_id>NCT01568944</nct_id>
  </id_info>
  <brief_title>Role of Infected Blood Dendritic Cells in Heart Disease Risk</brief_title>
  <official_title>Peripheral Blood Dendritic Cells and Periodontitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Dental and Craniofacial Research (NIDCR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Augusta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that blood dendritic cells harbor pathogens from the oral
      cavity in chronic periodontitis and disseminate these pathogens to atherosclerotic plaques.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To address this hypothesis, a clinical study in humans with moderate to severe chronic
      periodontitis has been designed. This is an interventional study involving scaling and root
      planing and two arms: 1. treatment with PO amoxocillin/metronidazole plus chlorhexidine oral
      rinse; 2. no antibiotics or oral rinse. It is expected that the antibiotics plus
      chlorhexidine will prevent the dendritic cell response to infection (bacteremia) elicited by
      scaling and root planing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in frequency of blood dendritic cells from baseline</measure>
    <time_frame>7, 8, 30 days</time_frame>
    <description>The frequency of blood dendritic cells at baseline will be compared to that after 7 days of PO antibiotics/mouthrinse therapy, 24 hours after Scaling and root planing (day 8) and 4-6 weeks after scaling and root planing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>probing attachment levels</measure>
    <time_frame>after 7 days, 24 hours, 4-6 weeks</time_frame>
    <description>Probing attachment levels will be monitored at baseline, 7 days after antibiotics, 24 hours after scaling and root planing and 4-6 weeks after scaling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum response</measure>
    <time_frame>7 days, 24 hours and 4-6 weeks</time_frame>
    <description>serum markers will be measured at baseline, after 7 days of antibiotics, 24 hours after scaling and root planing and 4-6 weeks after scaling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>probing depths</measure>
    <time_frame>after 7 days, 24 hours, 4-6 weeks</time_frame>
    <description>Probing depths will be monitored at baseline, 7 days after antibiotics, 24 hours after scaling and root planing and 4-6 weeks after scaling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plaque index</measure>
    <time_frame>after 7 days, 24 hours, 4-6 weeks</time_frame>
    <description>Plaque index of Silness and loe will be monitored at baseline, 7 days after antibiotics, 24 hours after scaling and root planing and 4-6 weeks after scaling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gingival index</measure>
    <time_frame>after 7 days, 24 hours, 4-6 weeks</time_frame>
    <description>gingival index of loe and silness will be monitored at baseline, 7 days after antibiotics, 24 hours after scaling and root planing and 4-6 weeks after scaling</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Chronic Periodontitis</condition>
  <arm_group>
    <arm_group_label>Oral Antibiotic and Oral Rinse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days. Subjects will also rinse their mouths with 2 ounces of 0.12% chlorhexidine/peridex mouthrinse two times per day. Subjects will also receive mechanical debridement at the baseline visit. Intervention Amoxicillin/Amoxil/lansoprazol 500 mg/ Metronidazole/Flagyl 250 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects assigned to standard treatment will receive full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Antibiotic and Oral Rinse</intervention_name>
    <description>PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID</description>
    <arm_group_label>Oral Antibiotic and Oral Rinse</arm_group_label>
    <other_name>Peridex/Flagyl/Amoxil/lansoprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard Treatment</intervention_name>
    <description>Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers</description>
    <arm_group_label>Oral Antibiotic and Oral Rinse</arm_group_label>
    <arm_group_label>Standard Treatment</arm_group_label>
    <other_name>Scaling</other_name>
    <other_name>Root planing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  generalized moderate to severe chronic periodontitis

        Exclusion Criteria:

          -  diabetes

          -  antibiotics treatment within 3 months

          -  treatment with steroids, phenytoin, cyclosporin, coumadin

          -  presence of conditions requiring prophylactic antibiotics per AHA

          -  cancer, HIV, hepB, lupus, prediagnosed heart disease, renal disease

          -  smoker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Cutler, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>GHSU-College of Dental Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GHSU-CDM Clinical Research Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zeituni AE, McCaig W, Scisci E, Thanassi DG, Cutler CW. The native 67-kilodalton minor fimbria of Porphyromonas gingivalis is a novel glycoprotein with DC-SIGN-targeting motifs. J Bacteriol. 2010 Aug;192(16):4103-10. doi: 10.1128/JB.00275-10. Epub 2010 Jun 18.</citation>
    <PMID>20562309</PMID>
  </reference>
  <reference>
    <citation>Zeituni AE, Carrion J, Cutler CW. Porphyromonas gingivalis-dendritic cell interactions: consequences for coronary artery disease. J Oral Microbiol. 2010 Dec 21;2. doi: 10.3402/jom.v2i0.5782.</citation>
    <PMID>21523219</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <last_update_submitted>January 27, 2015</last_update_submitted>
  <last_update_submitted_qc>January 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Augusta University</investigator_affiliation>
    <investigator_full_name>Christopher Cutler</investigator_full_name>
    <investigator_title>Assoc. Dean Dental Medicine, Dept. Chair Periodontics</investigator_title>
  </responsible_party>
  <keyword>periodontal</keyword>
  <keyword>disease</keyword>
  <keyword>dendritic</keyword>
  <keyword>cells</keyword>
  <keyword>antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Chronic Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

